TT-702 / Teon Therap, Cancer Research UK - LARVOL DELTA

Development and validation of an LC-MS/MS method for the quantification of novel therapeutic TT-478, a selective adenosine receptor 2B antagonist, for a phase I/II clinical trial. (PubMed, Bioanalysis) - P1/2 | "TT-478 is a novel adenosine receptor 2B antagonist, administered orally as a prodrug (TT-702) for the treatment of advanced metastatic prostate cancer in a Phase I/II clinical trial setting...A novel robust method to quantify TT-478 in human plasma has been fully validated and is currently being utilized in an ongoing clinical trial. Analysis of TT-478 levels in plasma samples from these patients will provide first-in-human pharmacokinetic data for this novel compound.Clinical trial registration: https://clinicaltrials.gov/study/NCT05272709?term=AREA%5BConditionSearch%5D(Advanced%20Prostate%20Cancer)%20AND%20AREA%5BBasicSearch%5D(phase%203%20drug)%20AND%20AREA%5BOverallStatus%5D(NOT_YET_RECRUITING%20OR%20RECRUITING%20OR%20ENROLLING_BY_INVITATION%20OR%20ACTIVE_NOT_RECRUITING)&rank=10 identifier is NCT05272709."

Journal • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

CURATE: TT-702 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - P1/2 | N=188 | Recruiting | Sponsor: Cancer Research UK | N=114 ➔ 188 | Trial completion date: Sep 2025 ➔ Jun 2027 | Trial primary completion date: Sep 2025 ➔ Jun 2027

Enrollment change • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • MLH1 • MSH2 • MSH6 • MSI • PGR

Cancer Research UK and Teon Therapeutics announce treatment of first patient in phase 1/2 trial for difficult-to-treat cancers (PMLive) - "Cancer Research UK and Teon Therapeutics have announced that the first patient has been successfully dosed in their phase 1/2 trial of Teon’s first-in-class oral, once-daily dosed adenosine receptor antagonist, TT-702, for the treatment of patients with a range of difficult-to-treat cancers...The trial is currently open to recruitment at The Royal Marsden and additional sites are anticipated to open shortly. The first group will receive increasing doses of TT-702 to assess the safety and tolerability of the drug and to confirm the maximum dose that can safely be given to patients."

Trial status • Oncology • Solid Tumor

CURATE: TT-702 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - P1/2 | N=114 | Recruiting | Sponsor: Cancer Research UK

Monotherapy • New P1/2 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • MLH1 • MSH2 • MSH6 • MSI • PGR

[VIRTUAL] TT-702, a selective and potent A2B receptor antagonist for the treatment of cancer (AACR 2021) - "By contrast, preladenant, an A2AR antagonist, had no effect on cancer cell growth and DC differentiation. TT-702, a novel, selective and potent A2B receptor antagonist, has the potential to treat a diverse range of hard-to-treat and aggressive tumors (including cold ones) as a monotherapy, and in combination with anti-PD-1, enzalutamide and other anticancer therapies. TT-702 exhibits excellent safety and PK profiles in animals and is slated to enter clinical development in 2021."

Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Melanoma • Oncology • Prostate Cancer • Solid Tumor • CD4 • CD8

Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference (PRNewswire) - "Teon Therapeutics...announced the forthcoming oral presentation of preclinical data on selective adenosine A2B receptor antagonist TT-702, at the American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10-15, 2021...'in vitro and in vivo data that validate TT-702's unique mechanism of action and its therapeutic effect as a single agent and synergistic effect when combined with immune checkpoint inhibitor in preclinical models'."

Preclinical • Oncology

Cancer Research UK teams up with Teon on new cancer drug (PharmaTimes) - "Cancer Research UK (CRUK) has signed a collaboration agreement with Teon Therapeutics to advance early clinical development of the latter’s new cancer drug...Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702...The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021....The drug will be evaluated as both a monotherapy and in combination with an anti-PD-1 immunotherapy or hormonal therapy."

Licensing / partnership • New P1/2 trial • Oncology

Teon Therapeutics Completes $30 Million Series A Financing (PRNewswire) - “The funds will be used to advance the company's lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company's pipeline…’ In collaboration with Cancer Research UK, we will advance our A2BR-selective antagonist TT-702 into the clinic later this year’…”

Clinical • Financing • Oncology